Potassium phosphates (injection)
پتاسیم فسفات (تزریقی)
🩸 Blood And Blood Forming OrgansElectrolyte replenisher
Market / country: 🇺🇸 USA
Potassium Phosphates (US)
🧮 Dose calculator
Hypophosphataemia · Regimen source: FDA Potassium phosphates · 2.1FDA Potassium phosphates · 2.2
🛡️ Safety & information
Contraindications
- ⛔ Hyperkalaemia; hyperphosphataemia; severe renal impairment (eGFR <30) or ESRD; hypercalcaemia or significant hypocalcaemia. FDA Potassium phosphates · 4
Warnings
- • Serious cardiac reactions with undiluted or rapid infusion; pulmonary embolism from precipitates (calcium phosphate); hyperkalaemia; hypocalcaemia; vein damage. FDA Potassium phosphates · 5
Formulations
- Phosphorus 3 mmol/mL (potassium 4.4 mEq/mL), 5/15 mL vials — injection 🇺🇸 USA FDA Potassium phosphates · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Potassium phosphates · 8.1
“Risk Summary Administration of the recommended dose of Potassium Phosphates Injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Potassium phosphates · 8.2
“Risk Summary Phosphorus and potassium are present in human milk.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Potassium phosphates · 8.4
“Safety and effectiveness of Potassium Phosphates Injection have been established in pediatric patients as a source of phosphorus: in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. for parenteral nutrition when oral or enteral nutrition …”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Potassium phosphates · 8.5
“In general, dose selection of Potassium Phosphates Injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA216274
- DailyMed (FDA label)FDA Potassium phosphates
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDB05XA06
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Potassium phosphates · 3FDA Potassium phosphates · 2.1FDA Potassium phosphates · 2.2FDA Potassium phosphates · 4FDA Potassium phosphates · 5FDA Potassium phosphates · SPL approval / marketing categoryFDA Potassium phosphates · 8.1FDA Potassium phosphates · 8.2FDA Potassium phosphates · 8.4FDA Potassium phosphates · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified